Modified Oligonucleotides for Specific PCR Amplification

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current PCR assays face challenges with non-specific amplification, primer dimers, and contamination, which reduce efficiency and increase costs due to the need for hot-start DNA polymerases and additional reagents like dUTP and UNG enzyme.

Innovation Solution

Employing thermostable RNase H enzymes and modified oligonucleotides with cleavage domains that inhibit primer extension until hybridization and are activated at elevated temperatures, eliminating the need for reversibly inactivated DNA polymerases and reducing non-specific amplification.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If primers are added to the reaction mixture at room temperature, then the reaction setup is simple and fast, but non-specific amplification and primer dimers form reducing assay efficiency

Engineering Contradiction:
Improvereaction setup simplicityVSAvoidamplification efficiency
Core Design Contradiction:
Ease of operationVSProductivity

Solution Approach 1:

The primer is pre-modified with a blocking group at the 3'-end before the reaction begins. This preliminary modification prevents non-specific amplification and primer dimer formation during reaction setup, while still allowing the primer to hybridize to the target sequence. The blocking group is then removed in-situ during the amplification process, enabling productive extension only after proper hybridization has occurred.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If hot-start DNA polymerase is used to prevent non-specific amplification, then amplification specificity improves, but the cost and complexity of the assay increase

Engineering Contradiction:
Improveamplification specificityVSAvoidassay complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The blocking group is chemically extracted or removed from the primer's 3'-end during the amplification process. This removal occurs only after the primer has successfully hybridized to the target sequence, ensuring that non-specific binding does not lead to amplification. The extracted blocking group can be released as a separate molecule, allowing the primer to then serve as an effective template for DNA polymerase extension.

Inventive Principle:
Principle #2Taking out (Extraction)

3Object-affected harmful factors

If additional reagents like dUTP and UNG enzyme are added to prevent contamination, then carry-over contamination is reduced, but the cost and number of reagents increase

Engineering Contradiction:
Improvecontamination resistanceVSAvoidnumber of reagents
Core Design Contradiction:
Object-affected harmful factorsVSQuantity of substance

Solution Approach 1:

The assay system performs its own contamination prevention function through the blocking group mechanism. By preventing non-specific amplification at the source through the modified primer, the system eliminates the need for additional anti-contamination reagents like dUTP and UNG enzyme. The blocking group effectively serves as a built-in safeguard that reduces carry-over contamination without requiring external chemical agents.

Inventive Principle:
Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enhances the specificity of PCR assays by minimizing non-specific amplification and primer dimers, reducing costs, and allowing for more efficient and accurate nucleic acid amplification and detection.

Implementation Method 1

RNase H enzymes and modified oligonucleotides with cleavage domains that inhibit primer extension until hybridization and are activated at elevated temperatures

Methodology Applied
Scientific EffectEnzyme: Enzyme

Data Source

PatentUS9434988B2RNase H-based assays utilizing modified RNA monomers
Publication Date: 2016.09.06 INTEGRATED DNA TECHNOLOGIES INC
  • US9434988B2 patent drawing
  • US9434988B2 patent drawing
  • US9434988B2 patent drawing

AI summary

The present invention provides methods of cleaving a nucleic acid strand to initiate, assist, monitor or perform biological assays.